First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

Last Updated: Thursday, May 15, 2025

Researchers examined the advantages and limitations of the molecular profiling tests Oncotype DX and Prosigna. They concluded that more research comparing the two tests is needed to harness these tests’ potential and to refine treatment decisions. Additionally, pairing both tests could help to identify patients who would benefit from chemotherapy.

Cancer Treatment Reviews

Anticancer Research

Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer

The Breast

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Journal of Clinical Oncology

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

Journal of Clinical Oncology

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Journal of Clinical Oncology

A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)

Biomedicines

Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer

Journal of Clinical Oncology

Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial

Journal of Clinical Oncology

Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial

HR+ HER2- Breast Cancer Resource Center

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

Anticancer Research

Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer

The Breast

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Journal of Clinical Oncology

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

Journal of Clinical Oncology

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Journal of Clinical Oncology

Biomedicines

Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer

Journal of Clinical Oncology

Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial

Journal of Clinical Oncology

Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer